Wechselwirkungen · Vocabria
400 mg Vocabria 400 mg prolonged-release suspension for injection 600 mg Vocabria 600 mg prolonged-release suspension for injection · Abschnitt 4.5 · PDF-Seite 9
HOS-143409 · Präparat HOS-099004
Cabotegravir is primarily metabolised by uridine diphosphate glucuronosyl transferase (UGT) 1A1 and to a lesser extent by UGT1A9. Medicinal products which are strong inducers of UGT1A1 or UGT1A9 are expected to decrease cabotegravir plasma concentrations leading to lack of efficacy (see section 4.3 and table 6 below). In poor metabolizers of UGT1A1, representing a maximum clinical UGT1A1 inhibition, the mean AUC, Cmax and Ctau of oral cabotegravir increased by up to 1.5-fold. The impact of an UGT1A1 inhibitor may be slightly more pronounced, however, considering the safety margins of cabotegravir, this increase is not expected to be clinically relevant. No dosing adjustments for Vocabria are, therefore, recommended in the presence of UGT1A1 inhibitors (e.g. atazanavir, erlotinib, sorafenib).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): atazanavir (HOS-086180) erlotinib (HOS-113527) sorafenib (HOS-115745) uridine (HOS-085192)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-09-09T14:50:00Z · SHA-256 5a6802905e0f35577ea123d161d3a8ece2c09d33762d2d6c349b5a0a60e5d7b9 · Passage 52632a71e0e65d73f2b5714ac13927e5967c486261f46481cfd0f692f1a4a33c · Zeichen 295–1097 im Abschnitt